Fresenius Medical Care AG & Co. KGaA Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 7/27/2026)
| Balance Sheet | Total Assets | 31,002,300,000.00 | ROE | 42.93 % |
| Balance Sheet | Total Equity | 13,309,800,000.00 | ROA | 3.16 % |
| Cashflow | Capital Expenditures | -915,369,000.00 | P/FCF | 5.93 |
| Cashflow | Free Cash Flow | 1,765,630,976.00 | – | – |
| Cashflow | Operating Cash Flow | 2,681,000,000.00 | P/CF | 3.91 |
| Income | Earnings per Share (diluted) | 3.50 | Div. Yield | 3.97 % |
| Income | Net Income | 978,367,000.00 | P/E | 10.71 |
| Income | Shares Outstanding | 279,289,000.00 | P/B | 0.79 |
| Income | Total Revenue | 19,627,600,000.00 | P/S | 0.53 |
Ratios calculated on: 10/14/2026
Company Description
Fresenius Medical Care AG & Co KGaA is a Germany-based holding and kidney dialysis company, operating in the fields of dialysis products and dialysis services. Its dialysis business is vertically integrated, providing dialysis treatment at its own dialysis clinics and supplying these clinics with a range of products. In addition, the Company sells dialysis products to other dialysis service providers. The Company operates in two business segments: North America and International. The North America segment consists of Renal Therapy Group and Fresenius Medical Services. The International segment consists of Europe and Latin America and one Asia-Pacific unit. During the year ended December 31, 2010, the Company's subsidiary, U.S. Vascular Access Holdings, LLC, completed the acquisition of National Vascular Care Inc.; it acquired a total of 168 existing clinics, and acquired Gambro AB's peritoneal dialysis (PD) business. The Company has a total of 1000 subsidiaries worldwide
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.freseniusmedicalcare.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more